Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New drugs; nitisinone].

A F Cohen1, H van Bronswijk

  • 1Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden. ac@chdr.nl

Nederlands Tijdschrift Voor Geneeskunde
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using machine learning techniques to characterize sleep-deprived driving behavior.

Traffic injury prevention·2021
Same author

Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

PloS one·2021
Same author

The use of machine learning improves the assessment of drug-induced driving behaviour.

Accident; analysis and prevention·2020
Same author

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Pharmacological reviews·2020
Same author

Correction to: Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019
Same author

Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019

Nitisinone treats hereditary tyrosinaemia by inhibiting 4-hydroxyphenyl-pyruvate dioxygenase (4HPPD). This action prevents toxic tyrosine metabolite buildup in a life-threatening metabolic disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Hereditary tyrosinaemia is a life-threatening metabolic disorder.
  • It results from a deficiency in an enzyme essential for tyrosine catabolism.
  • Toxic tyrosine metabolites accumulate, causing severe health issues.

Purpose of the Study:

  • To investigate the therapeutic role of Nitisinone.
  • To understand its mechanism in treating hereditary tyrosinaemia.

Main Methods:

  • Nitisinone functions as an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase (4HPPD).
  • 4HPPD is an enzyme involved early in the tyrosine catabolic pathway.

Main Results:

  • Nitisinone effectively inhibits 4HPPD activity.

Related Experiment Videos

  • This inhibition prevents the accumulation of toxic tyrosine metabolites.

    • Conclusions:

    • Nitisinone is a key therapeutic agent for hereditary tyrosinaemia.
    • Its mechanism involves blocking early steps in tyrosine breakdown to prevent toxicity.